S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
NFLX   476.62 (-2.38%)
GILD   59.89 (-0.37%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
NFLX   476.62 (-2.38%)
GILD   59.89 (-0.37%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
NFLX   476.62 (-2.38%)
GILD   59.89 (-0.37%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
S&P 500   3,577.59 (+0.56%)
DOW   29,591.27 (+1.12%)
QQQ   290.39 (+0.00%)
AAPL   113.85 (-2.97%)
MSFT   210.11 (-0.13%)
FB   268.43 (-0.47%)
GOOGL   1,727.56 (-0.51%)
AMZN   3,098.39 (-0.03%)
TSLA   521.85 (+6.58%)
NVDA   525.60 (+0.40%)
BABA   270.11 (-0.23%)
CGC   24.72 (+4.22%)
GE   10.07 (+3.18%)
MU   64.18 (+4.53%)
AMD   85.31 (+0.79%)
T   28.62 (+1.06%)
NIO   55.38 (+12.45%)
F   8.86 (+1.37%)
ACB   7.18 (+0.70%)
NFLX   476.62 (-2.38%)
GILD   59.89 (-0.37%)
BA   211.53 (+5.97%)
DIS   145.98 (+3.48%)
Log in
NASDAQ:BPMC

Blueprint Medicines Stock Forecast, Price & News

$98.76
+1.11 (+1.14 %)
(As of 11/23/2020 04:41 PM ET)
Add
Compare
Today's Range
$96.70
Now: $98.76
$100.16
50-Day Range
$92.08
MA: $100.12
$106.84
52-Week Range
$43.29
Now: $98.76
$108.50
Volume545,824 shs
Average Volume632,551 shs
Market Capitalization$5.50 billion
P/E Ratio18.22
Dividend YieldN/A
Beta0.95
Blueprint Medicines Corporation develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.
Read More
Blueprint Medicines logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.91 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BPMC
CUSIPN/A
Phone617-374-7580
Employees420

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$66.51 million
Book Value$23.68 per share

Profitability

Net Income$-347,690,000.00

Miscellaneous

Market Cap$5.50 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableOptionable
$98.76
+1.11 (+1.14 %)
(As of 11/23/2020 04:41 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BPMC News and Ratings via Email

Sign-up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions

How has Blueprint Medicines' stock been impacted by Coronavirus?

Blueprint Medicines' stock was trading at $52.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BPMC shares have increased by 87.8% and is now trading at $98.45.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Blueprint Medicines?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 5 hold ratings, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Blueprint Medicines
.

What stocks does MarketBeat like better than Blueprint Medicines?

Wall Street analysts have given Blueprint Medicines a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Blueprint Medicines wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Blueprint Medicines' next earnings date?

Blueprint Medicines is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Blueprint Medicines
.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) released its quarterly earnings data on Tuesday, November, 3rd. The biotechnology company reported $11.16 earnings per share for the quarter, beating the Zacks' consensus estimate of $6.49 by $4.67. The biotechnology company earned $745.10 million during the quarter, compared to the consensus estimate of $627.42 million. Blueprint Medicines had a return on equity of 43.72% and a net margin of 41.08%. Blueprint Medicines's quarterly revenue was up 8087.9% compared to the same quarter last year. During the same quarter last year, the business earned ($1.93) earnings per share.
View Blueprint Medicines' earnings history
.

What price target have analysts set for BPMC?

15 Wall Street analysts have issued 12-month target prices for Blueprint Medicines' stock. Their forecasts range from $77.00 to $135.00. On average, they anticipate Blueprint Medicines' stock price to reach $104.29 in the next twelve months. This suggests a possible upside of 5.9% from the stock's current price.
View analysts' price targets for Blueprint Medicines
.

Are investors shorting Blueprint Medicines?

Blueprint Medicines saw a decrease in short interest in October. As of October 30th, there was short interest totaling 3,700,000 shares, a decrease of 15.5% from the October 15th total of 4,380,000 shares. Based on an average trading volume of 436,100 shares, the short-interest ratio is currently 8.5 days.
View Blueprint Medicines' Short Interest
.

Who are some of Blueprint Medicines' key competitors?

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

Who are Blueprint Medicines' key executives?

Blueprint Medicines' management team includes the following people:
  • Mr. Jeffrey W. Albers M.B.A., J.D., MBA, CEO, Pres & Director (Age 49, Pay $977.18k)
  • Mr. Alexis A. Borisy, Co-Founder & Director (Age 48, Pay $45k)
  • Mr. Michael Landsittel, CFO & Treasurer (Age 48, Pay $478.98k)
  • Ms. Kathryn Haviland, Chief Operating Officer (Age 44, Pay $624.19k)
  • Ms. Tracey L. Mccain, Exec. VP, Chief Legal Officer, Chief Compliance officer & Sec. (Age 52, Pay $631.63k)
  • Mr. Anthony L. Boral, Chief Medical Officer (Age 57, Pay $664.21k)
  • Ms. Ariel Hurley, Principal Accounting Officer, VP of Fin. & Controller (Age 46)
  • Dr. Fouad Namouni, Pres of R&D
  • Dr. Christopher K. Murray, Sr. VP of Technical Operations (Age 57)
  • Dr. Marion Dorsch, Chief Scientific Officer (Age 55)

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.59%), State Street Corp (3.25%), JPMorgan Chase & Co. (2.45%), Alkeon Capital Management LLC (1.61%), Perceptive Advisors LLC (1.19%) and Victory Capital Management Inc. (1.11%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Debra Durso-Bumpus, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch, Mark Alan Goldberg and Nicholas Lydon.
View institutional ownership trends for Blueprint Medicines
.

Which major investors are selling Blueprint Medicines stock?

BPMC stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., BlackRock Inc., State Street Corp, SG Americas Securities LLC, Rothschild & Co. Asset Management US Inc., BNP Paribas Arbitrage SA, Perceptive Advisors LLC, and Emerald Advisers LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Anthony L Boral, Ariel Hurley, Christina Rossi, Debra Durso-Bumpus, George Demetri, Jeffrey W Albers, Kate Haviland, Marion Dorsch, Mark Alan Goldberg, and Nicholas Lydon.
View insider buying and selling activity for Blueprint Medicines
.

Which major investors are buying Blueprint Medicines stock?

BPMC stock was purchased by a variety of institutional investors in the last quarter, including Natixis, JPMorgan Chase & Co., Alkeon Capital Management LLC, Lord Abbett & CO. LLC, Assenagon Asset Management S.A., Sib LLC, Victory Capital Management Inc., and Tygh Capital Management Inc..
View insider buying and selling activity for Blueprint Medicines
.

How do I buy shares of Blueprint Medicines?

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $98.45.

How big of a company is Blueprint Medicines?

Blueprint Medicines has a market capitalization of $5.49 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 420 workers across the globe.

What is Blueprint Medicines' official website?

The official website for Blueprint Medicines is www.blueprintmedicines.com.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]

This page was last updated on 11/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.